UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.316

Sortiert nach

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Annals of oncology, 2018-12, Vol.29 (12), p.2334-2340

2018

Volltextzugriff (PDF)

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions

Journal of the European Academy of Dermatology and Venereology, 2011-12, Vol.25 (s5), p.1-51

2011

Volltextzugriff (PDF)

Activation of p38 Mitogen‐Activated Protein Kinase and c‐Jun‐NH2‐Terminal Kinase by BMP‐2 and Their Implication in the Stimulation of Osteoblastic Cell Differentiation

Journal of bone and mineral research, 2003-11, Vol.18 (11), p.2060-2068

2003

Volltextzugriff (PDF)

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of oncology, 2018-10, Vol.29, p.viii120-viii120

2018

Volltextzugriff (PDF)

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

Annals of oncology, 2019-05, Vol.30, p.iii47-iii47

2019

Volltextzugriff (PDF)

The Marathon of the Messenger: A History of Messenger RNA Vaccines

1, 2023

Volltextzugriff (PDF)

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

Annals of oncology, 2018-10, Vol.29, p.viii93-viii93

2018

Volltextzugriff (PDF)

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer

Annals of oncology, 2015-08, Vol.26 (8), p.1692-1697

2015

Volltextzugriff (PDF)

Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)

Annals of oncology, 2018-10, Vol.29, p.viii621-viii621

2018

Volltextzugriff (PDF)

Cellules tumorales circulantes et réponse pathologique complète : facteurs pronostiques indépendants dans le cancer du sein inflammatoire traité par chimiothérapie néo-adjuvante combinée au bevacizumab (analyse de deux essais multicentriques de phase II BEVERLY−1 et −2)

Revue d'épidémiologie et de santé publique, 2017-05, Vol.65, p.S54-S54

2017

Volltextzugriff (PDF)

1ISG-027 Carbon footprint of a sterilisation unit

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A4-A4

2021

Volltextzugriff (PDF)

Protein Kinase C-independent Activation of Protein Kinase D Is Involved in BMP-2-induced Activation of Stress Mitogen-activated Protein Kinases JNK and p38 and Osteoblastic Cell Differentiation

The Journal of biological chemistry, 2004-01, Vol.279 (1), p.259-264

2004

Volltextzugriff (PDF)

Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathway

Experimental cell research, 2004-07, Vol.297 (1), p.235-246

2004

Volltextzugriff (PDF)

Reconstructions physique et sportive en France sous la IVe République (1946-1958)

2018

Volltextzugriff (PDF)

Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts

Journal of cellular biochemistry, 2001-01, Vol.81 (1), p.68-81

2001

Volltextzugriff (PDF)

Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway

The Journal of biological chemistry, 2001-08, Vol.276 (31), p.29028-29036

2001

Volltextzugriff (PDF)

Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation

The Journal of biological chemistry, 2004-08, Vol.279 (35), p.36259-36267

2004

Volltextzugriff (PDF)

Difficultés de production et d’approvisionnement en nouveaux radiopharmaceutiques n’ayant pas d’autorisation de mise sur le marché : réflexion à partir d’une étude multicentrique nationale française

Médecine nucléaire : imagerie fonctionelle et métabolique, 2016-04, Vol.40 (2), p.152-159

2016

Volltextzugriff (PDF)

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome

The Journal of clinical investigation, 1998-03, Vol.101 (6), p.1310-1317

1998

Volltextzugriff (PDF)

Aide au codage des emplois : l’outil CAPS

Archives des maladies professionnelles et de l'environnement, 2014-06, Vol.75 (3), p.S30-S30

2014

Volltextzugriff (PDF)

Increased Expression of Protein Kinase Cα, Interleukin‐1α, and RhoA Guanosine 5′‐Triphosphatase in Osteoblasts Expressing the Ser252Trp Fibroblast Growth Factor 2 Apert Mutation: Identification by Analysis of Complementary DNA Microarray

Journal of bone and mineral research, 2001-04, Vol.16 (4), p.705-712

2001

Volltextzugriff (PDF)

Reconstructions physique et sportive en France sous la IVe République (1946-1958): Entre intentions et réalisations

2018

Volltextzugriff (PDF)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

BMJ open, 2022-03, Vol.12 (3), p.e055821-e055821

2022

Volltextzugriff (PDF)

1 – 25 von 1.316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(886)
Mit Volltextzugriff
(1.094)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(330)
Humans
(293)
Life Sciences & Biomedicine
(242)
Animals
(149)
Female
(121)
Male
(111)
Mice
(99)
Biological And Medical Sciences
(98)
Life Sciences
(71)
Sciences Biologiques Et Medicales
(59)
Adult
(58)
Physical Sciences
(57)
Immunology
(56)
Medical Sciences
(56)
Sciences Medicales
(52)
Middle Aged
(47)
Fundamental And Applied Biological Sciences. Psychology
(46)
Humanities And Social Sciences
(46)
Biochemistry & Molecular Biology
(40)
Physics
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Activation of p38 Mitogen‐Activated Protein Kinase and c‐Jun‐NH2‐Terminal Kinase by BMP‐2 and Their Implication in the Stimulation of Osteoblastic Cell Differentiation

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

The Marathon of the Messenger: A History of Messenger RNA Vaccines

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer

Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

Cellules tumorales circulantes et réponse pathologique complète : facteurs pronostiques indépendants dans le cancer du sein inflammatoire traité par chimiothérapie néo-adjuvante combinée au bevacizumab (analyse de deux essais multicentriques de phase II BEVERLY−1 et −2)

1ISG-027 Carbon footprint of a sterilisation unit

Protein Kinase C-independent Activation of Protein Kinase D Is Involved in BMP-2-induced Activation of Stress Mitogen-activated Protein Kinases JNK and p38 and Osteoblastic Cell Differentiation

Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathway

Reconstructions physique et sportive en France sous la IVe République (1946-1958)

Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts

Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway

Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation

Difficultés de production et d’approvisionnement en nouveaux radiopharmaceutiques n’ayant pas d’autorisation de mise sur le marché : réflexion à partir d’une étude multicentrique nationale française

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome

Aide au codage des emplois : l’outil CAPS

Increased Expression of Protein Kinase Cα, Interleukin‐1α, and RhoA Guanosine 5′‐Triphosphatase in Osteoblasts Expressing the Ser252Trp Fibroblast Growth Factor 2 Apert Mutation: Identification by Analysis of Complementary DNA Microarray

Reconstructions physique et sportive en France sous la IVe République (1946-1958): Entre intentions et réalisations

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Suchergebnisse filtern